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Abstract
Objectives To measure the mass transfer and clearance of procalcitonin (PCT) in patients with septic
shock during continuous venovenous hemofiltration (CVVH), and to assess the mechanisms of
elimination of PCT.
Setting The medical department of intensive care.
Design A prospective, observational study.
Patients Thirteen critically ill patients with septic shock and oliguric acute renal failure requiring
continuous venovenous postdilution hemofiltration with a high-flux membrane (AN69 or polyamide) and
a ‘conventional’ substitution volume (<2.5l/hour).
Measurements and main results PCT was measured with the Lumitest PCT Brahms® in the prefilter
and postfilter plasma, in the ultrafiltrate at the beginning of CVVH (T0) and 15 min (T15′), 60 min
(T60′) and 6 hours (T6h) after setup of CVVH, and in the prefilter every 24 hours during 4 days. Mass
transfer was determined and the clearance and the sieving coefficient were calculated according to
the mass conservation principle. Plasma and ultrafiltrate clearances, respectively, at T15′, T60′ and
T6h were 37±8.6ml/min (not significant) and 1.8±1.7ml/min (P<0.01), 34.7±4.1ml/min (not
significant) and 2.3±1.8ml/min (P<0.01), and 31.5±7ml/min (not significant) and 5±2.3ml/min
(P<0.01). The sieving coefficient significantly increased from 0.07 at T15′ to 0.19 at T6h, with no
difference according to the nature of the membrane. PCT plasma levels were not significantly modified
during the course of CCVH.
Conclusions We conclude that PCT is removed from the plasma of patients with septic shock during
CCVH. Most of the mass is eliminated by convective flow, but adsorption also contributes to elimination
during the first hours of CVVH. The effect of PCT removal with a conventional CVVH substitution fluid
rate (<2.5l/hour) on PCT plasma concentration seems to be limited, and PCT remains a useful
diagnostic marker in these septic patients. The impact of high-volume hemofiltration on the PCT
clearance, the mass transfer and the plasma concentration should be evaluated in further studies.
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Introduction
Procalcitonin (PCT) is induced in the plasma of patients with
sepsis and septic shock, and is a very useful marker to
monitor treatment in critically ill patients [1]. This polypeptide
of 166 amino acids is specifically increased in generalized
bacterial or fungal infections, whereas neither local bacterial
or viral infection colonization only leads to a small elevation or
no elevation of PCT.
Since the first report of Assicot and colleagues in 1993,
numerous studies have confirmed PCT as a very strong
marker of inflammation in the fields of infectious diseases,
pediatric care and critical care [2]. Measurements of PCT
during multiple organ dysfunction syndrome also provide
information about the severity and the course of the disease,
with an association between PCT concentration and Sepsis-
related Organ Failure Assessment (SOFA) or Acute Physiol-
ogy, Age, Chronic Health Evaluation (APACHE) II scores [3].
An early decline of PCT is observed in patients who recov-
ered and survived, and PCT can also be used as an adequate
treatment indicator. This marker of inflammation homeostasis
seems more specific and sensitive to monitor septic patients
as compared with C-reactive protein, or even cytokines that
are not so easy to routinely measure.
The main site of production and the distribution rate of PCT
remain unknown, but there is evidence that it may be the
leukocytes or neuroendocrine cells in the bronchial epithelium
and the liver. Experimental kinetics have demonstrated that
the secretion of PCT occurs within less than 4 hours after ini-
tiation of sepsis and that PCT is probably stimulated by tumor
necrosis factor or IL-6 secretion since these cytokines peak
before the appearance of PCT in plasma [4]. After the injec-
tion of bacterial endotoxin in healthy subjects, PCT increased
by approximately 0.5ng/ml per hour after a latency of about
2–3 hours, reaching a plateau after 6–12 hours and falling to
their baselines values within the following 2 days.
Hoffman and colleagues recently demonstrated that PCT
amplifies nitric oxide synthase gene expression and nitric
oxide production, which is an explanation for the observed
correlation between PCT concentration and the fatal
outcome in multiple organ dysfunction syndrome and septic
shock [5]. Elimination of PCT is not well known. Like other
plasma proteins, PCT is probably degraded by proteolysis.
Renal excretion of PCT plays a minor role and there is no
accumulation of PCT in cases of patients with severe renal
failure. We recently demonstrated in hemodialysis patients
that PCT is positively correlated with currently used markers
of inflammation such as C-reactive protein and fibrinogen,
and it is negatively correlated with markers of nutritional
status such as albumin. This relationship remains stable even
in patients without infection, with low values of PCT concen-
tration (<1ng/ml), suggesting a relationship between inflam-
mation, nutritional status, atherosclerosis and cardiovascular
mortality in chronic renal failure [6]. Nevertheless, there is no
relation between serum creatinin and plasma PCT concentra-
tions [7].
In critically ill patients, renal failure is an early and frequent
complication, occurring in 19% of sepsis cases, 23% of
severe sepsis cases and 51% of septic shock cases [8], with
renal replacement therapy in 63–75% of the patients [9].
Continuous venovenous hemofiltration (CVVH) is actually the
method of choice for renal replacement therapy in critically ill
and hemodynamic instable patients. Clinical beneficial effects
in septic patients (improved PaO2/FiO2, decreased vasopres-
sor requirements, increased cardiac index) directed the clini-
cians to a new paradigm in a nonrenal indication and to
adjunctive treatment of CVVH in sepsis, leading to more inter-
est in cytokine removal [10]. Little is known about PCT in
patients treated with CVVH. This protein of molecular weight
(MW) 13,000Da could be removed from the plasma by con-
vection or adsorption.
The reduction of PCT is known to be associated with a better
prognosis. In experiments designed for the immunomodula-
tion hypothesis, Nylen and colleagues observed an increased
mortality rate in an animal model of sepsis following intra-
venous injection of PCT. This was avoided when the animals
were pretreated with PCT antiserum [11]. In a septic patient
treated with CVVH, therefore, the ideal marker should be
obtained with a minimally invasive technique as routine,
should reflect the inflammatory status, should distinguish
infectious diseases from noninfectious inflammatory diseases,
should be without any relation to the acute phase response
and biocompatibility of the membrane, and should be corre-
lated to the severity score and prognosis. PCT seems to be
this marker. Nevertheless, in the case of alteration of the PCT
concentration during renal replacement therapy, diagnostic
and therapeutic decisions might be influenced.
The aims of this study were to measure the mass transfer and
clearance of PCT during ‘conventional’ CVVH (substitution
<2.5l/hour) with a hypermeable membrane in patients with
septic shock, and to determine the mechanism of elimination
and its impact on the plasma concentration in the course of
convective therapy.
Materials and methods
In this prospective study from January 2000 to June 2001,
informed written consent was obtained from the relatives of the
patients. The inclusion criterion were age >18 years old, septic
shock (American College of Chief Physicians [ACCP]/Society
of Critical Care Medicine [SCCM] conference consensus)
[12], and anuric acute renal failure with or without multiple
organ dysfunction syndrome. All the patients were monitored
with a Swann–Ganz catheter to optimize the inotropic support
and fluid expansion. Bacteriological data were obtained in 72%
of the patients in order to prescribe an adequate antibiotherapy
in the different etiologies in sepsis (pneumonia, peritonitis,
cutaneous infection, intra-abdominal infection or urinary tractR162
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infection). All the patients were mechanically ventilated, 60% of
them with acute respiratory distress syndrome
(PaO2/FiO2=137±20mmHg). No patients were treated with
corticosteroids or drotrecogin alpha.
Technique
Blood samples were taken from the prefilter (inlet filter
plasma concentration [Ci]) and postfilter (outlet filter plasma
concentration [Co]) sites of the extracorporeal circulation.
The ultrafiltrate was collected directly from the outlet of the
hemofilter (ultrafiltrate concentration [Cuf]). PCT was mea-
sured with the Lumitest PCT Kit (Brahms® Diagnostica,
Berlin, Germany), an immunoluminometric assay with two
specific monoclonal antibodies bound to PCT at two different
sites (katacalcin and calcitonin segments). One of the anti-
bodies is luminescence labeled. Immediately after centrifuga-
tion, and after 90 min incubation, luminescence was
measured in the blood and ultrafiltrate samples. The samples
were taken at the beginning of CVVH (T0) and at the follow-
ing times, according to the kinetics of PCT and to the lowest
degree of clotting formation on the dialyzer membrane during
these intervals of sampling: T0, Ci; after 15 min (T15′), after
60 min (T60′) and after 6 hours (T6h) of CVVH, Ci, Co and
Cuf; and after 12 hours, after 24 hours and every 24 hours
during 4 days (J1–J4) of CVVH.
In a preliminary study we determined the intra-assay and
interassay variation, from 5% to 2.5% for PCT values from
1.3ng/ml to 66ng/ml, respectively. The reproducibility was
guaranteed for blood samples and also for ultrafiltrate
samples. There is no interaction between the PCT dosage
and heparin treatment, antibiotics, vasoactive drugs or seda-
tive drugs. The hematocrit before and after the hemofilter was
measured to exclude an alteration of the PCT measurement
due to the hemoconcentration.
CVVH procedure
Venous access was achieved with a 11–14Fr double lumen
catheter into the internal jugular or femoral vein. The pump-
assisted circuit was the Prisma® or the BSM 22 (Hospal SA,
Lyon France–Gambro SA, Colombes, France). Postdilutional
bicarbonate buffered substitution fluid was used with an ultra-
filtration rate of 1.5–2l/hour, and the net ultrafiltration rate
was 100ml/hour. Blood flow of 150ml/min was adapted with
pressure monitoring. Two high-flux synthetic membranes
were used: AN69 M100 (Hospal SA), 0.9m2 Kuf,
37±7ml/hour per mmHg; or polyamide Polyflux 14S
(Gambro SA), 1.4m2 Kuf, 50ml/ hour per mmHg. Nonfrac-
tional heparin was used with an initial dose of
400–1000IU/hour with adaptation of the infusion to the
patient and the clotting time.
Calculation
The following formulae were used, according to the mass
conservation principle. All flows and clearances are
expressed in milliliters per minute.
Total inlet mass (Mi) = inlet plasma flow rate (Qi) × 
inlet filter plasma concentration (Ci)
Total outlet mass (Mo) = outlet plasma flow rate (Qo) ×
outlet filter plasma concentration (Co)
Total mass transfer (plasma) (MTp) = Mi – Mo
Total mass transfer (ultrafiltrate) (MTuf) = 
ultrafiltrate flow rate (Quf) × ultrafiltrate concentration (Cuf)
Ultrafiltrate concentration (Cuf) = 
Ci × sieving coefficient (SC)
Absorbed mass (Mab) = MTp – MTuf
Plasma clearance (CLp) = MTp / Ci
Ultrafiltrate clearance (CLuf) = MTuf / Ci (equation 1) 
= Quf × SC (equation 2)
Sieving coefficient (SC) = 2Cuf / [Ci + Co]
Inlet plasma flow rate (Qi) = inlet blood flow (Qb) × 
(1 – prefilter hematocrit [Ht])
Outlet plasma flow rate (Qo) = Qi – Quf
Statistical analysis
Results are presented as the mean±standard deviation.
Comparisons of measured and calculated data were per-
formed using analysis of variance or the Mann–Witney and
Wilcoxon range test as appropriate to their distribution
(Statview 5.0®; SAS Institute, Berkeley, CA, USA). The rela-
tionships between various parameters were studied by
regression analysis with Pearson’s correlation matrix, and
were calculated using Fischer’s z  test. The level of signifi-
cance was given for P<0.05.
Results
Thirteen patients (nine male, four female) were included in
this study. Clinical characteristics and biological data at T0
are reported in Table 1. All patients were anuric. CVVH tech-
nical data were an inlet blood flow of 160±46ml/min, an
ultrafiltrate flow rate of 28±2ml/min and a net ultrafiltration
rate of 111±42ml/hour, with no change for each patient
during the course of CVVH. Eight patients were treated with
AN69 membrane and five patients with polyamide membrane.
Ten patients died, with a significant difference in the Simpli-
fied Acute Physiology Score (SAPS) II compared with sur-
vivors (63±14 versus 31±29, P<0.05). The patients
selected were critically ill and justly explained this mortality
with a high median multiple organ failure syndrome. During
the first 24 hours of CVVH, there was no significant change
in arterial mean pressure, norepinephrine and dobutamine
requirement for all the patients. From J1 to J4, we observed aR163
significant decrease of norepinephrine requirement
(1.02±0.47γ/kg per min versus 0.86±0.47γ/kg per min,
P<0.05) and a significant increase of mean arterial pressure
(76±12mmHg versus 82±11mmHg, P<0.05), but with no
relation and change with PCT plasma clearance.
During the follow-up period from T0 to T6h, PCT was
detected in the ultrafiltrate in all patients. The plasma clear-
ance was 37.4±8.7ml/min at T15′, with a very low variability
from patient to patient and from the PCT plasma concentra-
tion. PCT clearance at T15′ therefore seems to be linked to
the CVVH techniques but not to the inflammatory status. The
low variability of these results has also been confirmed at
T60′ and T6h. There was no significant change in plasma
clearance over time: 34.7±4.1ml/min at T60′, and
31.5±7ml/min at T6h (not significant). The sieving coeffi-
cient of PCT was low, 0.07 at T15′ and 0.09 at T60′, but sig-
nificantly increased to 0.19 at T6h (P<0.05). The ultrafiltrate
clearance was 1.85±1.7ml/min at T15′, with a significant
increase to 2.3±1.8ml/min at T60′ and 5±2.3ml/min at T6h
(P<0.01). There was no difference for plasma and ultrafil-
trate clearance when we compared the AN69 group and the
polyamide group during the follow-up period. The calculated
adsorbed mass was 38% of the total inlet mass at T15′, 31%
at T60′ and 25% at T6h, with a significant decrease of this
ratio during the follow-up period. The results are presented in
Table 2.
Discussion
In the present study, we demonstrate that PCT is partially
removed from the plasma to the ultrafiltrate, with elimination
of a significant mass of this 13,000Da protein. Plasma clear-
ance was calculated from 37.8 to 30ml/min without a signifi-
cant difference from T15′ to T6h during CVVH. For all
patients, the CVVH procedure was constant. Most of the
mass of PCT is eliminated by convective flow, with no doubt
Available online http://ccforum.com/content/7/6/R160
Table 1
Characteristics of the 13 patients
Clinical data Biological data at T0
Age (years), 61.5±9 Procalcitonin (ng/ml), 114±66
Sex, 9 male/4 female C-reactive protein (mg/l), 198±91
SAPS II score, 56±21 Creatinin (µg/l), 452±158
Organ failure (n), 4.6±1 Potassium (mmol/l), 4.9±1.1
Mean arterial pressure (mmHg), 71±14 Bicarbonate (mmol/l), 18±3
Norepinephrine (γ/kg per min), 1±04 Lactate (mmol/l), 8.2±5.9
Dobutamine (γ/kg per min), 12.5±4 Leucocytes (count/ml), 15,700±8400
Cardiac index (l/min per m2), 5±1.9 Hematocrit (%), 29±7
Systemic vascular resistance (dyn/s per cm5), 630±210 Fibrinogen (g/l), 6.2±2
Delay to CVVH (days), 2.5±1.8 Albumin (g/l), 21±9
Data presented as mean±standard deviation. T0, beginning of continuous venovenous hemofiltration (CVVH); SAPS, Simplified Acute Physiology
Score.
Table 2
Mass transfer, clearance and sieving coefficient of procalcitonin
T15′ T60′ T6h
Total inlet mass (ng/min) 10,663±17,660 11,264±19,122 10,713±19,571
Total outlet mass (ng/min) 6438±12,595 7503±13962 7538±15,558
Total mass transfer (ultrafiltrate) (ng/min) 102±154 170±265 526±764
Mad (ng/min) 4122±6263 3591±5401 2647±3901
Plasma clearance (ml/min) 37.4±8.7* 34.7±4.16* 31.5±7*
Ultrafiltrate clearance (ml/min) 1.85±1.73** 2.37±1.8** 5.01±2.31**
Sieving coefficient 0.07±0.07** 0.09±0.07** 0.19±0.1**
Data presented as mean±standard deviation. T15′, 15 min after setup of continuous venovenous hemofiltration (CVVH); T60′, 60 min after setup
of CVVH; T6h, 6 hours after setup of CVVH. * Not significant, **P < 0.05.R164
that clearance in convective treatment essentially depends on
the ultrafiltration and substitution rate. In similar conditions of
CVVH (AN69 membrane, 0.9m2, substitution rate of 2l/hour),
Brunet and coworkers demonstrated that β2-microglobulin
(MW 12,000 Da near from PCT) had a clearance value in the
same range, confirming the fact that convection is more effi-
cient than diffusion in removing middle molecular weight
solutes [13]. Using a substitution rate from 1.5 to 2.5l/hour,
so-called ‘conventional’ CVVH, one could easily adapt the
clearance (ml/min) to the effusion flow (ml/hour) [13].
Our results were in accordance with most of the previous
studies on PCT clearance in the same range of ultrafiltration
rate. In the study by Meisner and colleagues (26 septic
patients, 1.25m2 polysulfone filter, 1.2l/hour ultrafiltration
rate, 10ml/min blood flow), the plasmatic clearance was
10ml/min after 12 hours of CVVH and 17ml/min after
24 hours of CVVH, with an ultrafiltrate clearance from 2 to
5ml/min in the same interval [14]. Dahaba and colleagues
also found similar results for plasmatic and ultrafiltrate clear-
ance in similar conditions of CVVH [15]. In the present study
we used the postdilution technique, which reduces clear-
ances of most solutes by about 15% at an ultrafiltrate flow of
2000ml/hour [13].
Adsorption to the membrane also contributes to elimination of
PCT. This mechanism is major during the first hours of CVVH.
The total adsorbed mass/total inlet mass ratios are 38% at
T15′, 31% at T60′ and 25% at T6h (P<0.01). This observa-
tion probably reflects the progressive coating and saturation
of the filter in the early phase of CVVH. The sieving coeffi-
cients were low (0.07 and 0.09) at T15′ and T60′, with a sig-
nificant increase at T6h to 0.19 (P<0.05). These results are
in the expected range described for other solutes of similar
MW: M100 [Hospal SA], creatinin (MW113Da) = 1,
β2-microglobulin (MW13,000DA) = 0.65, myoglobin (MW
17,000Da) = 0.35, IL-1β (MW17,000) = 0.18, tumor necrosis
factor alpha, trimeric (MW54,000Da) = 0.06, albumin
(MW69,000Da)<0.01; Polyflux 14S [Gambro SA], creatinin =
1, β2-microglobulin = 0.63, myoglobin = 0.3, albumin<0.01.
The sieving coefficient describes the passage of a solute
through the membrane, with a maximal value of 1 when the fil-
tration is complete.
Our results thus indicate that about 20% of PCT is removed
throughout the membrane. The membrane structure strongly
affects the results in convective therapy [16]. Moreover,
recent data clearly show that a synthetic membrane appears
to confer a significant survival advantage over a cellulose-
based membrane [17]. In our study, we used AN69 or
polyamide membranes, two synthetic and biocompatible
high-flux permeability membranes. The geometry and proper-
ties of theses two membrane with a symmetric (AN69) or an
asymmetric (polyamide) structure and neutral or negative
electric charges easily explain its adsorptive capacity [18].
The electrostatic interaction is also a function of the pH and
the flow through the hemofilter. For instance, adsorption of a
globally positive molecule such as cytochrome C (MW
12,300Da) on the AN69 membrane is maximal at pH 7.4 and
linearly increases with the wall shear rate and the electrical
differential potential [19]. The cut-off of 35–40kDa allows the
filtration of PCT but, according to the European Renal Asso-
ciation guidelines, AN69 is classified as of very high adsorp-
tive capacity while polyamide is defined only as of
Critical Care    December 2003 Vol 7 No 6 Level et al.
Figure 1
Procalcitonin (PCT) plasma concentration and clearance kinetics during continuous venovenous hemofiltration (CVVH). (a) PCT ultrafiltrate
clearances (± standard deviation, ml/min) at 15 min (T15′), 60 min (T60′) and 6 hours (T6h) after setup of CVVH (*P < 0.01). 
(b) PCT plasma clearances (± standard deviation, ml/min) at T15′, T60′ and T6h (** not significant). (c) PCT plasma concentration (±standard
deviation, ng/ml) at the beginning of CVVH (T0) and every 24 hours during 4 days (J1–J4) (*** not significant). Cluf, ultrafiltrate clearance; Clp,
plasma clearance.
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intermediate adsorptive capacity [20]. In our study, we found
no difference in patients treated with the AN69 membrane or
with the polyamide membrane.
As shown in Fig.1, the ultrafiltrate clearance significantly
increased while the plasma clearance remained stable and
the adsorbed mass/total inlet mass ratio significantly
decreased. This relation between the ultrafiltration rate and
the plasma clearance has been previously described in
animal models of cytokine mass transfer, and has been
described with the concept of additional clearance. In this
hypothesis, the total clearance increased with ultrafiltration
flow but also with a progressive coating and adsorption on
the membrane, which is itself optimized with the increase of
the substitution volume during the course of CVVH [10]. An
increase in the middle MW range solutes clearance has also
been demonstrated recently with a reduction of the inner
diameter of hollow fibers in the polysulfone hemofilter, so-
called ‘internal filtration’ [21].
Figure 1 demonstrates that median plasma levels of PCT
were not significantly altered during CVVH in all patients.
PCT levels also remained essentially unchanged in blood that
was related to the serious illness of the patients. The kinetics
of PCT during CVVH, however, is difficult to interpret. The
production of PCT essentially depends on the evolution of
the sepsis and its response to infectious injury while it does
not seem to be induced by an extracorporeal circuit, as has
been shown in studies in patients with cardiopulmonary
bypass [14]. On the contrary, the observed decrease of PCT
plasma concentration is probably more the consequence of
an adequate antibiotherapy than of the elimination by CVVH.
Dahada and colleagues differ from us in this opinion and tried
to demonstrate a significant decrease of PCT, IL-6 and tumor
necrosis factor alpha in septic patients during the first
12 hours of CVVH (AN69 membrane, 0.9m2, 2l/hour,
100ml/min blood flow) [15]. In their study, they proposed to
change the hemofilters every 12 hours and explained their
efficiency with the very high adsorptive capacity of AN69.
From this point of view, a coupled plasma filtration adsorption
with a resin or carbon column is another interesting solution
[22]. If there is no doubt that cytokines could be removed by
CVVH then reports demonstrating a significant fall in the
serum levels of inflammatory mediators are scarce, especially
during CVVH with a ‘conventional’ substitution rate
(<2.5l/hour) [10,23–27]. The PCT clearance measurement
and its impact on plasma concentration should be evaluated
in studies with high-volume hemofiltration.
Conclusions
We conclude that PCT is removed from the plasma of
patients with septic shock during CCVH. Most of the mass is
eliminated by convective flow, but adsorption also contributes
to elimination during the first hours of CVVH. The effect of
PCT removal with a conventional CVVH substitution fluid rate
(<2.5l/hour) on the PCT plasma concentration seems to be
limited, and PCT remains a useful diagnostic marker in these
septic patients. The impact of high-volume hemofiltration on
the PCT clearance, the mass transfer and the plasma con-
centration should be evaluated in further studies.
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